Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

231
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
231
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

487
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
487
Neural Regulation01:37

Neural Regulation

39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transthoracic ultrasound localization microscopy of myocardial vasculature in patients.

Nature biomedical engineering·2024
Same author

Ultrafast 3-D Transcutaneous Super Resolution Ultrasound Using Row-Column Array Specific Coherence-Based Beamforming and Rolling Acoustic Sub-aperture Processing: In Vitro, in Rabbit and in Human Study.

Ultrasound in medicine & biology·2024
Same author

Long-term expandable mouse and human-induced nephron progenitor cells enable kidney organoid maturation and modeling of plasticity and disease.

Cell stem cell·2024
Same author

Data-Driven Dynamic Internal Model Control.

IEEE transactions on cybernetics·2024
Same author

Assessment of rainfall-derived inflow and infiltration in sewer systems with machine learning approaches.

Water science and technology : a journal of the International Association on Water Pollution Research·2024
Same author

Determining the net input fluxes of pollutants based on the spatial source apportionment receptor model for early warning of regional soil pollution.

Journal of hazardous materials·2024

Related Experiment Video

Updated: Jun 10, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K

Levodopa therapy affects brain functional network dynamics in Parkinson's disease.

Xiaojin Liu1, Yuze Zhang2, Yihe Weng3

  • 1Center for Educational Science and Technology, Beijing Normal University, Zhuhai 519087, China; School of Psychology, Center for Studies of Psychological Application, Guangdong Key Laboratory of Mental Health and Cognitive Science, South China Normal University, Guangzhou 510631, China; Key Laboratory of Brain, Cognition and Education Sciences (South China Normal University), Ministry of Education, Guangzhou 510631, China.

Progress in Neuro-Psychopharmacology & Biological Psychiatry
|October 14, 2024
PubMed
Summary

Levodopa (L-dopa) therapy alters brain functional network dynamics in Parkinson's disease (PD) patients. L-dopa treatment reduced connectivity variability in key brain networks, offering new insights into PD pharmacotherapy.

Keywords:
Dynamic functional connectivityFunctional network topologyL-dopa therapyResting-state fMRI

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

15.6K

Related Experiment Videos

Last Updated: Jun 10, 2025

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

2.6K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

3.6K
Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
14:27

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data

Published on: June 26, 2013

15.6K

Area of Science:

  • Neuroscience
  • Radiology
  • Pharmacology

Background:

  • Levodopa (L-dopa) is the primary pharmacological treatment for Parkinson's disease (PD) motor symptoms.
  • The impact of L-dopa on the dynamic functional connectivity (dFC) of brain networks remains incompletely understood.

Purpose of the Study:

  • To investigate the effects of L-dopa on brain functional network dynamics in PD patients.
  • To analyze changes in dFC states, variability, and network topology following L-dopa administration.

Main Methods:

  • Resting-state functional MRI (fMRI) data were collected from 26 PD patients before (PD-OFF) and after (PD-ON) receiving 400 mg L-dopa.
  • Independent component analysis and a sliding-window approach were used to estimate dFC and its temporal properties.

Main Results:

  • PD patients on L-dopa (PD-ON) exhibited a decreased mean dwell time in a sparsely connected state compared to PD-OFF.
  • L-dopa treatment led to more frequent transitions between dFC states.
  • Reduced dFC variability was observed within the auditory and sensorimotor networks in PD-ON patients.

Conclusions:

  • L-dopa therapy significantly modulates brain functional network dynamics in Parkinson's disease.
  • Findings suggest L-dopa influences the temporal organization and stability of neural networks.
  • This study provides novel insights into the neural mechanisms underlying L-dopa's therapeutic effects in PD.